Treats obsessive compulsive disorder (OCD). ANDA 212182, held by Bionpharma. Fluvoxamine Maleate.
As of Nov 16, 2026, ANDA 212182 (Fluvoxamine Maleate), held by Bionpharma, was first approved by FDA on May 11, 2020, with 2 approved supplements and 0 published complete response letters.
Fluvoxamine maleate extended-release capsules are selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive compulsive disorder (OCD). Efficacy was demonstrated in: One 12-week study with fluvoxamine maleate extended-release capsules in adults. Two 10-week studies with immediate-release (IR) fluvoxamine tablets in adults and one 10-week study with IR fluvoxamine tablets in children and adolescents ( 14.1, 14.3 ). One maintenance study with IR fluvoxamine tablets. 1.1 Obsessive Compulsive Disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 11, 2020 | Original application | Approved | None posted |
| Fluvoxamine Maleate150MG · capsule, extended release;oral | Fluvoxamine Maleate | Rx |
| Fluvoxamine Maleate100MG · capsule, extended release;oral | Fluvoxamine Maleate | Rx |
| Nov 21, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 18, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 11, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters